Insight Molecular Diagnostics to Showcase Leadership in Kidney Transplant Management at Conferences in Singapore and Orlando

Core Insights - Insight Molecular Diagnostics Inc. (iMDx) is actively participating in two significant industry conferences to showcase its GraftAssure™ technology and its clinical kitted test under development [1][4] - The company aims to highlight the clinical applications of transplant rejection testing, particularly in longitudinal surveillance and therapeutic response monitoring [2][3] Conference Participation - iMDx is hosting a symposium at the IATDMCT annual meeting in Singapore from September 21 to 24, 2025, focusing on the benefits of in-house testing for transplant rejection [2][6] - The company will also present at the ASHI annual meeting in Orlando, Florida, from October 6 to 10, 2025, discussing GraftAssureIQ, a research-use-only test kit [4][8] Technology and Product Development - GraftAssure technology is designed to detect transplant rejection and monitor treatment response, significantly reducing time-to-rejection diagnosis in high-risk kidney transplant patients [3][5] - The GraftAssureDx, currently in development, is expected to be submitted for FDA review by the end of 2025, targeting an estimated $1 billion addressable market for kitted transplant rejection testing [5][15] Strategic Partnerships - iMDx is collaborating with Bio-Rad Laboratories to present on GraftAssureIQ, emphasizing the potential of in-house testing for convenience and efficiency in transplant care [4][5] Market Position - The company is focused on democratizing access to molecular diagnostic testing, particularly for kidney transplant patients, utilizing donor-derived cell-free DNA (dd-cfDNA) as a biomarker for transplant rejection [16][13]